SILTRAX EPI NO. 10

Produit de santé naturel homologué au Canada

Titulaire: Pascal International Corporation
NPN ou DIN-HM: 02097729
Statut: Licence active
Date de licence: 10 octobre 2007
Date de révision: Non renseignée
Forme: Ficelle
Voie d'administration: Buccale, Dentaire
Type de demande: DIN de transition

L’analyse des doses orales ne s’applique pas sans voie exclusivement orale établie.

Composition

Composition médicinale non renseignée.

Ingrédients non médicinaux

Eau purifiée, Phosphate de sodium, monobasique, Cotton Cord Twisted # 9, éthanol anhydre, Hydroxyde d'ammonium, Chlorure de zinc, alcool benzylique, Sodium Dithionite, Chlorure de sodium, Sodium Bisulfite, Sodium Thiosulphate, anhydrous, Acide phosphorique

Doses recommandées au Canada

Population	Âge	Quantité par prise	Fréquence
Enfants	Non précisée	minimum : 1 cord	Non précisée
Adultes	Non précisée	minimum : 1 cord	Non précisée

Usages autorisés au Canada

Use whenever gingival retraction is advisable in dental practice; as preceding impression taking with any elastic impression material; or prior to placement of caps, crowns, bridges, etc. SIL-TRAX EPI is braided cotton cord saturated with a solution of Racemic epinephrine hydrochloride dried by a technique which retains the activity of the medication. Normal tissue moisture reactivates the medication, which promptly retracts gingival tissue in a manner that causes no tissue damage, yet fully exposes the gingival margin.

Un usage autorisé au Canada n'est pas une allégation de santé autorisée dans l'Union européenne. Consultez le registre des allégations de santé.

Mises en garde au Canada

Précautions et mises en garde
Retraction with an epinephrine cord should be limited to the equivalent of one normal quadrant of the mouth per appointment.
Contre-indications
SIL-TRAX EPI is contraindicated for persons who are epinephrine sensitive, or for persons suffering from cardiovascualr disease, diabetes, or hyperthyroidism.
Effets indésirables connus
Contains Sodium Bisulfate, a sulfite that may cause allergic types of reactions including anaphylactic symptoms and life-threatening or less severe asthmatic episodes in certain susceptible people. The overall prevalence of sulfite sensitivity in the general population is unknown and probably low. Sulfite sensitivity is seen more frequently in asthmatic than in non-asthmatic people.